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Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis on binding to its receptors, death receptor 4 and
5 (DR4, DR5). TRAIL can also activate c-Jun N-terminal kinase (JNK) through the adaptor molecules, TNF receptor-associated factor
2 (TRAF2) and receptor-interacting protein (RIP). The role of JNK in TRAIL-induced tumour cell apoptosis is unclear. In this study, we
demonstrate that JNK is activated by TRAIL in colon cancer cells. Inhibition of JNK with L-JNKI reduced rhTRAIL-induced cell death
but enhanced cell death induced by selective activation of DR4 or DR5. This difference was unrelated to receptor internalisation or
differential activation of c-Jun, but activation of different JNK isoforms. Our data demonstrate that JNK1, but not JNK2 is activated by
rhTRAIL in the examined colon cancer cell lines. Although rhTRAIL activated both the long and short isoforms of JNK1, selective
activation of DR4 or DR5 led to predominant activation of the short JNK1 isoforms (JNK1a1 and/or JNK1b1). Knockdown of JNK1a1
by shRNA enhanced apoptosis induced by TRAIL, agonistic DR4 or DR5 antibodies. On the other hand, knockdown of the long
JNK1 isoforms (JNK1a2 and JNK1b2) had the opposite effect; it reduced TRAIL-induced cell death. These data indicate that the short
JNK1 isoforms transmit an antiapoptotic signal, whereas the long isoforms (JNK1a2 or JNK1b2) act in a proapoptotic manner.
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Tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a member of the TNF ligand superfamily (Ashkenazi
and Dixit, 1998). TRAIL induces apoptosis on binding to its
transmembrane, death domain-containing receptors, TRAIL
receptors 1 (death receptor 4; DR4) and 2 (death receptor 5;
DR5). Three other TRAIL-binding receptors exist, but they are
unable to transmit an apoptotic signal and thus considered to be
‘decoy receptors’. Decoy receptor 1 (DcR1) lacks the transmem-
brane and intracellular domains and is anchored to the plasma
membrane via a glycosylphosphatidylinositol-tail. Decoy receptor
2 (DcR2) possesses a truncated, non-functional death domain,
whereas the third decoy receptor, osteoprotegerin is a secreted,
soluble receptor (Ashkenazi and Dixit, 1998).
Binding of homotrimeric TRAIL to DR4 and DR5 induces
receptor trimerisation and activation leading to recruitment of
adaptor proteins and formation of the death-inducing signalling
complex (DISC). Procaspase-8 and/or -10 are recruited to the
DISC, leading to their oligomerisation and activation. Active
caspase-8/-10 can activate the executioner caspases (procaspase-3,
-6 and -7) and/or initiate the mitochondrial apoptotic pathway by
cleaving the BH3-only protein Bid.
Generally, caspase activation is the main outcome following
activation of DR4/5 by TRAIL. However, TRAIL, via adaptor
molecules such as TNF receptor-associated factor 2 (TRAF2),
receptor-interacting protein (RIP), and the mitogen-activated
protein kinase kinases (MKK)-4 and -7, can also activate the
c-Jun N-terminal kinase (JNK) pathway (Hu et al, 1999; Lin et al,
2000). JNK activation is also regulated by scaffold proteins, JNK-
interacting protein (JIP) and JNK stress-activated protein kinase-
associated protein 1 (JSAP1) (Whitmarsh et al, 1998; Ito et al,
1999). Depending on the cell type and the stimulus, JNK can
activate a number of diverse downstream targets including
members of the activator protein-1 (AP-1) family, c-Jun, JunD,
activating transcriptional factor 2 (ATF2), Bcl-2 proteins, c-Myc
and p53 (Bode and Dong, 2007; Lin et al, 2007). Whether JNK
induces or suppresses apoptosis is largely dependent on the
molecules it activates. For example, JNK can both phosphorylate
antiapoptotic Bcl-2 proteins to promote apoptosis or phosphor-
ylate proapoptotic Bcl-2 proteins (e.g. BAD) to inhibit apoptosis
(Maundrell et al, 1997; Yu et al, 2004).
JNK proteins are encoded by three genes, jnk1, jnk2 and jnk3.
Jnk1 and jnk2 encode ubiquitously expressed JNK proteins
whereas the jnk3 protein product is primarily found in the brain,
heart and to a lesser extent in the testis (Bode and Dong, 2007).
Alternative splicing of the jnk transcripts results in 10 different
JNK isoforms each of which may target different transcription
factors (Gupta et al, 1996). JNK1 and -2 have four isoforms each
(a1, a2, b1 and b2). JNK1a1, JNK1b1, JNK2a1 and JNK2b1
isoforms all have a molecular weight of 46 kDa, whereas JNK1a2,
JNK1b2, JNK2a2 and JNK2b2 isoforms are larger due to an
extended C-terminus and their molecular weight is 54 kDa. JNK3
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has two isoforms, JNK3a1 (46 kDa) and JNK3a2 (54 kDa). The
a- and b-isoforms correspond to two alternative stretches of
sequences in the kinase subdomains IX and X (Gupta et al, 1996).
The mechanism and role of JNK activation in TRAIL-induced
tumour cell apoptosis has not been fully elucidated. Some reports
suggest that JNK is not activated by TRAIL in colon cancers
regardless of their sensitivity to TRAIL (Zhang et al, 2004),
whereas others suggest that JNK activation augments TRAIL-
induced apoptosis in a number of other tumours (Herr et al, 1999;
Li et al, 2006; Mikami et al, 2006). The reason for this discrepancy
is currently not known. It was therefore of interest to investigate
which JNK isoforms are activated by which TRAIL receptor and
how the different JNK isoforms contribute to TRAIL-induced
colon cancer cell death.
MATERIALS AND METHODS
Cell culture and treatments
Colo205 cells were obtained from American Tissue Culture
Collection (ATCC, Manassas, VA, USA). HCT15 and HCA7 cells
were a kind gift from Professor L Egan (University College
Hospital, Galway). Colo205 and HCT15 cells were maintained in
RPMI-1640 medium and HCA7 in DMEM medium, both media
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine,
50 U ml1 penicillin and 50 mg ml1 streptomycin at 371C, 5% CO2
in a humidified incubator. Cells were treated with rhTRAIL (non-
tagged, fragment of amino acids 114–281; Triskel Therapeutics,
Groningen, The Netherlands), agonistic anti-DR4 or anti-DR5
antibodies (Novartis Pharmaceuticals, Basel, Switzerland). To
inhibit JNK activation, L-JNKI (Calbiochem, San Diego, CA,
USA), a cell-permeable, 21-amino-acid peptide inhibitor of
activated JNK was added 30 min before treatment with TRAIL or
agonistic antibodies. UV treatment was done at 25 J m2 for 3 min
as a positive control. All reagents were from Sigma-Aldrich
(St Louis, MO, USA) unless otherwise stated.
Cell viability assay
Cell viability was monitored by 2-(4, 5-dimethyltriazol-2-yl)-2, 5-
diphenyl tetrazolium bromide (MTT) assay as described before
(Szegezdi et al, 2006).
Cell death assay
Cell death was monitored by labelling phosphatidyl serine on the
surface of apoptotic cells with Annexin-V-FITC. Following
treatment, cells were collected by gentle trypsinisation and
incubated for 10 min at 371C to allow membrane recovery after
trypsinisation, pelleted by centrifugation at 350 g and incubated
with Annexin-V-FITC in calcium buffer (10 mM HEPES/NaOH, pH
7.4, 140 mM NaCl and 2.5 mM CaCl2) for 15 min on ice in the dark.
A wash step in calcium buffer was carried out before acquisition
on a FacsCalibur flow cytometer (Becton Dickinson, Oxford,
England).
Protein lysate preparation and western blot analysis
Cells were lysed in a buffer containing 1% Triton X-100, 100 mM
Tris/HCl pH 8.0, 200 mM sodium chloride (NaCl), 5 mM EDTA,
10% glycerol, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsul-
phonyl fluoride (PMSF), 5mg ml1 aprotinin, 2.5mg ml1 leupeptin,
1 mM sodium orthovanadate (Na2VO3) and 1 mM sodium fluoride
(NaF). Cellular proteins (30mg) were separated by electrophoresis
on 10% SDS polyacrylamide gel and transferred onto nitro-
cellulose membranes. Blots were incubated with rabbit monoclonal
antibodies to total JNK, phospho (p)-JNK (1 : 1000; Cell Signaling
Technology, Beverly, MA, USA), JNK1 (1 : 1000; BD Pharmigen,
San Diego, CA, USA) or mouse monoclonal antibodies to p-JNK
(1 : 500), Caspase-8 (1 : 1000; Cell Signaling Technology) and JNK2
(1 : 1000; Santa Cruz Technologies, Santa Cruz, CA, USA). For
detection, the appropriate horseradish peroxidase-conjugated goat
secondary antibodies were used. Protein bands were visualised
with SuperSignal West Pico Chemiluminescent Substrate (Pierce,
Rockford, IL, USA) on X-ray film (Agfa, Mortsel, Belgium).
In-vitro kinase assay (GST p-c-Jun)
JNK activity was measured using a specific kit (Cell Signaling
Technology) following the manufacturer’s instructions and using
GST fusion peptide as the specific substrate for JNK. In brief, cell
lysates (100mg protein) were incubated overnight at 41C with
GST-c-Jun fusion protein beads. After washing, the beads were
resuspended in kinase buffer containing ATP and kinase reaction
was allow to proceed for 30 min at 301C. Reactions were stopped by
the addition of polyacrylamide gel electrophoresis (PAGE) sample
loading buffer. Proteins were separated by electrophoresis on a
10% PAGE gel, transferred on PVDF membrane and incubated
with phospho-c-Jun (Ser63) antibody. Finally, blots were subjected
to enhanced chemiluminescence and kinase activity determined by
densitometric analysis.
Cell surface expression of TRAIL receptors
Cells were washed twice in PBS containing 1% BSA and then
incubated with monoclonal antibodies to DR4 or DR5 (Alexis,
Lausen, Switzerland) for 40 min. After two wash steps with PBS/
BSA, anti-mouse IgG-FITC (Sigma) secondary antibody was added
for 30 min. All incubations were carried out on ice. Negative
controls contained isotype control antibody. Cells were analysed
by FacsCalibur flow cytometer (Becton Dickinson).
Measurement of receptor internalisation by flow
cytometric analysis
To measure cellular uptake of receptor bound TRAIL and agonistic
DR4/5 antibody, 2 105 Colo205 cells were incubated at 4 or 371C
in the presence of 50 ng ml1 FITC-conjugated TRAIL or agonistic
DR4/5 antibody cross-linked with FITC-labelled anti-mouse anti-
body for 30 min. Samples were rapidly chilled on ice to inhibit
endocytosis and cells were collected by a brief centrifugation at
41C. After washing twice in prechilled wash buffer (20 mM Hepes,
pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2), cell
surface-bound ligand/antibody was removed by resuspension in
prechilled acid wash solution (0.2 M NaCl, 0.2 M acetic acid) for
5 min on ice. Cells were subsequently washed three times in wash
buffer and resuspended in cold PBS containing 2% (w/v) FBS
before immediate quantification of ligand internalisation using a
FacsCalibur flow cytometer (Becton Dickinson).
Immunoprecipitation of JNK
Cells were lysed in phosphate lysis buffer (PLB) containing 20 mM
sodium phosphate, 137 mM NaCl, 25 mM sodium-b-glycerol
phosphate, 2 mM sodium pyrophosphate, 2 mM EDTA, 1% Triton
X-100, 10% glycerol, 1 mM DTT, 1 mM PMSF, 5 mg ml1 aprotinin,
2.5mg ml1 leupeptin, 1 mM Na2VO3 and 1 mM NaF with soni-
cation. To cross-link mouse monoclonal JNK1 (BD Pharmigen)
and p-JNK (Cell Signaling Technology) antibodies to protein
G-sepharose beads (Sigma), 2 mg antibody was incubated with 30 ml
of beads for 1 h at 41C, washed twice with PLB, resuspended in
0.2 M sodium borate pH 9.0 containing 20 mM dimethylpimelidate
(DMP) and incubated for 45 min at room temperature. The
reaction was stopped by washing the beads once with 0.2 M
ethanolamine/HCl pH 8.0 and incubating at room temperature
for 2 h. The beads were washed twice in 200 mM glycine and
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200 mM NaCl pH 2.5 followed by a wash in 500 mM Tris/HCl pH
8.0. Protein (300mg) was incubated for 2 h at 41C with cross-linked
JNK1 or p-JNK (all isoforms) antibodies bound to protein
G-Sepharose. After two rounds of washes with PLB, the beads were
resuspended in 30ml of 1X Laemmli buffer. The supernatant was
loaded on a 10% SDS–PAGE acrylamide gel and transferred to
nitrocellulose membranes. Membranes containing the JNK1 immu-
noprecipitates were incubated with mouse monoclonal JNK1 (BD
Pharmigen) and rabbit monoclonal p-JNK (Cell Signaling Technol-
ogy) antibodies to identify which JNK1 isoforms were activated.
Membranes of the p-JNK immunoprecipitates were probed with JNK2
(Santa Cruz) and rabbit monoclonal total p-JNK (Cell Signaling
Technology) antibodies to identify the JNK2 isoforms activated.
Detection and visualisation was carried out as described above.
Transient transfections and plasmids
Cells (2 106) were pelleted and resuspended in transfection
solution V (Amaxa, Walkersville, MD, USA) containing 2.5mg of
mammalian JNK1a1 siRNA and the negative control expression
plasmid, pKD-JNK1a1/SAPK1c-v1 (Millipore, Billercia, MA, USA;
Catalogue no. 62-270, target sequence undisclosed) and pKD-
NegCon-v1 (Catalogue no. 62-002; Millipore), or siRNA against
JNK1a2/b2 and GFP as negative control by nucleofection using
program T13 as per manufacturer’s protocol (Amaxa).
GFP plasmid (2.5 mg) was also transfected to analyse transfec-
tion efficiencies. Twenty-four hours after transfection, cells were
resuspended in RPMI-1640 and seeded for Annexin V assays, RNA
isolation or protein sampling. Sequence of JNK1a2/b2 siRNA1:
sense–UUAGGUGCAGCAGUGAUCAtt; JNK1a2/b2 siRNA2: sense–
UAGGUGCAGCAGUGAUCAAtt; GFP sense–GGCUACGUCCAGGA
GCGCACCtt.
RNA isolation, cDNA synthesis, RT– PCR
Total RNA was isolated from cells using the GenElute Mammalian
Total RNA Extraction kit (Sigma). Reverse transcription was
carried out with 2 mg total RNA and oligo(dT) (Invitrogen, Paisley,
Scotland) using 20 U/25 ml reaction avian myeloblastosis virus
reverse transcriptase. cDNAs for genes of interest were amplified
during 32 cycles of 30 s denaturation at 941C, 30 s annealing at
561C, and 60 s extension at 721C, with the following primers:
JNK1a1 reverse – TCA CTG CTG CAC CTG TGC TAA AGG,
forward – TGC CAC AAA ATC CTC TTT CCA GGA; JNK1 reverse –
TCT TGG TTC TCT CCT CCA AGT C, forward – GTC AGG CAA
GGG ATT TGT TAT; JNK1b1 reverse – ACT GCT GCA CCT GTG
CTA AAG GAG, forward – AGG TGG TGT TTT GTT CCC AGG
TAC, GAPDH was used as a loading control; GAPDH reverse –
TCC ACC ACC CTG TTG CTG; forward – ACC ACA GTC CAT
GCC ATC. The binding sites of the isoform specific primers in
relation to the different JNK splice variants are depicted in
Supplementary Figure 2.
Statistical analysis
Differences in Annexin V staining between the treatment groups
were analysed used a non-paired Student’s t-test, with a significance
of Po0.05. Error bars are shown as standard error of mean (s.e.m.).
All statistical analysis was carried on Graphpad Prism 4 (GraphPad
Software Inc., La Jolla, CA, USA).
RESULTS
Colo205, HCT15 and HCA7 colon cancer cells are sensitive
to TRAIL
To examine the sensitivity of colon cancer cells to TRAIL, Colo205,
HCT15 and HCA7 cells were treated with increasing concentra-
tions of rhTRAIL for 24 h and cell viability assessed by MTT assay
(Figure 1). All three cell lines express both DR4 and DR5 on their
surface (Supplementary Figure 1; Figure 2C). The viability of all
three cell lines decreased in a dose-dependent manner. Colo205
cells were the most sensitive to rhTRAIL, with 10 ng ml1 of
rhTRAIL sufficient to decrease cell viability by 61.8±2.3%
(Figure 1A). HCT15 and HCA7 cells were less sensitive to
rhTRAIL. In these cell lines, a maximal decrease in cell viability
to 65.5±3.6% and 80.3±3.0%, respectively, was achieved follow-
ing treatment with 50 ng ml1 of rhTRAIL. No further decrease in
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Figure 1 Colo205, HCT15 and HCA7 colon cancer cells are sensitive to
TRAIL. (A) Colo205 cell viability after treatment with increasing
concentration of rhTRAIL (0–20 ng ml1) for 24 h measured by MTT
assay. (B) HCT15 and (C) HCA7 cell viability after treatment with
increasing concentration of rhTRAIL (0–250 ng ml1) for 24 h measured by
MTT assay. The graphs show average viability expressed as percentage of
control±s.d. of three independent experiments.
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viability was observed with rhTRAIL concentration 450 ng ml1
(Figure 1B and C).
TRAIL activates the JNK pathway in colon cancer cell lines
via both DR4 and DR5
To examine whether the JNK pathway was activated during
TRAIL-induced colon cancer cell death, phosphorylation of JNK
and its target, c-Jun were assessed by western blot analysis
following treatment with rhTRAIL. rhTRAIL (20 ng ml1 for
Colo205 and 50 ng ml1 for HCT15 and HCA7 cells) resulted in
phosphorylation of JNK in all three cell lines (Figure 2A).
Phosphorylation of c-Jun followed a similar pattern (Figure 2B).
To elucidate whether JNK phosphorylation was mediated by DR4
or DR5, Colo205 and HCT15 cells were treated with agonistic
antibodies against DR4 or DR5. Both cell lines were found to
express DR4 and DR5 on the cell surface and ligation of both
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Figure 2 TRAIL can activate the JNK pathway via both DR4 and DR5 in colon cancer cell lines. (A) Western blot analysis of total JNK and p-JNK in
Colo205, HCT15 and HCA7 cell lysates following treatment with 20 ng ml1 rhTRAIL for Colo205 cells and 50 ng ml1 for HCT15 and HCA7 for the times
indicated. Total JNK levels and actin were also detected as loading controls. (B) Western blot analysis of total c-Jun and p-c-Jun levels in Colo205, HCT15
and HCA7 cell lysates following rhTRAIL treatment as above. (C) Cell surface expression of DR4 and DR5 in Colo205 and HCT15 cells measured by
immunostaining followed by flow cytometry. Each histogram shows an overlay of a negative control (21 AB), DR4 and DR5 receptors. (D) Apoptosis-
inducing potential of DR4 and DR5 in Colo205 and HCT15 cells. Cells were treated with cross-linked agonistic DR4 or DR5 antibodies (5 nM for Colo205
and 10 nM for HCT15) or rhTRAIL (20 and 50 ng ml1 for Colo205 and HCT15) for 3 h in Colo205 cells and for 5 h in HCT15 cells. Apoptosis induction
was measured with Annexin V. The graphs show averaged percentage of apoptotic cells±s.e.m. of three independent experiments. (E) Western blot
analysis showing activation of JNK via DR4 and DR5 in Colo205 and HCT15 cells. Cells were treated with agonistic DR4 and DR5 antibodies (5 nM for
Colo205 cells and 10 nM for HCT15 cells) for the times indicated. JNK phosphorylation was detected in whole cell lysates. The images shown are
representatives of three independent experiments. Actin was detected as a loading control.
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receptors led to induction of apoptosis (Figure 2C and D). Colo205
cells were more sensitive to the DR5-agonistic antibody
(44.3%±3.5 and 27%±1.5 cell death induction by anti-DR5- and
anti-DR4 antibodies, respectively). The DR4- and DR5 antibodies
(10 nM) induced almost equal levels of apoptosis in HCT15 cells
(DR4, 49.8±3.1% and DR5, 45.3±5.7%) measured at 5 h after
treatment.
Ligation of both DR4 and DR5 could induce JNK phosphoryla-
tion (Figure 2E) in both cell lines. In Colo205 cells, DR5 ligation
induced a stronger JNK phosphorylation. This may correlate
with the stronger apoptosis-inducing ability of DR5 in these
cells (Figure 2E). Agonistic antibody treatment of HCT15 cells
demonstrated that the DR4 and DR5 receptors can equally trigger
JNK phosphorylation, which was detected maximally after 2 h
treatment (Figure 2E). These data suggest that both DR4 and DR5
can induce JNK activation.
Inhibition of JNK potentiates apoptosis-induction by
selective activation of DR4 or DR5, but reduces apoptosis
induced by rhTRAIL
In colon cancer cells, the role of JNK in death receptor-induced
apoptosis has not been fully elucidated. One of the most selective
JNK inhibitors currently available is the JNK-inhibitory peptide
analogue, L/D-JNKI (Barr et al, 2002) and thus was chosen to
inhibit JNK to examine the role of JNK in TRAIL-induced colon
carcinoma cell apoptosis. Inhibition of JNK by L-JNKI was
confirmed by measuring JNK activity in TRAIL- and UV-treated
HCT15 cells with an in vitro kinase assay (Figure 3A).
Colo205 and HCT15 cells were treated with rhTRAIL or agonistic
DR4/5 antibodies with or without L-JNKI of 50mM, a concentration
generally used due to the short half-life time of the inhibitor
pretreatment (Bonny et al, 2001). Inhibition of JNK activity in
Colo205 cells reduced TRAIL-induced apoptosis (Figure 3B;
P¼ 0.0041), however enhanced agonistic DR4- (P¼ 0.0002) and
DR5 antibody-induced cell death (P¼ 0.0006; Figure 3B). A similar
pattern, albeit to a lesser extent, was observed with HCT15 cells.
Inhibition of JNK activity again resulted in a significant increase in
DR5 but not DR4 antibody-induced apoptosis (P¼ 0.310; P¼ 0.041,
respectively). On the other hand (as was observed in Colo205 cells),
inhibition of JNK reduced rhTRAIL-induced apoptosis (P¼ 0.0254;
Figure 3C). This surprising result can be explained by either different
JNK isoform activation or different JNK compartmentalisation
induced by the different treatments.
Receptor internalisation occurs following treatment with
rhTRAIL and agonistic DR4/5 antibodies
On ligation by TRAIL, the TRAIL receptor-ligand complexes can
be internalised and surface bound vs internalised TNF receptors
have been shown to induce different signal transduction pathways
resulting different cellular responses (Schutze et al, 1999;
Schneider-Brachert et al, 2004; Varfolomeev et al, 2005; Kohlhaas
et al, 2007). We hypothesised that unlike rhTRAIL, agonistic DR4/
5 antibodies do not trigger receptor internalisation resulting in
JNK activation in a different cellular compartment. Colo205 cells
were treated with FITC-labelled rhTRAIL or agonistic DR4/5
antibodies cross-linked by a FITC-labelled secondary antibody for
30 min at either 371C or þ41C and their internalisation analysed by
flow cytometry. An acid wash step was carried out at þ41C after
the incubation to remove all non-internalised, surface bound
ligand/antibody ensuring that any fluorescent signal was due to
internalised ligand/antibody-receptor complexes. The flow cyto-
metric analysis showed that both rhTRAIL and agonistic
antibodies bound to the TRAIL receptors at both 371C and þ41C
and were all internalised to a similar extent, when incubated at
371C but not at þ41C (Figure 4A and B). The same samples were
also tested for the ability of rhTRAIL and agonistic antibodies to bind
to and activate their receptors in these conditions. At the end of the
30 min incubation, unbound rhTRAIL or agonistic antibodies were
removed by a wash step. The samples were incubated for an
additional 3 h and induction of apoptosis was detected as a measure
of receptor activation. The extent of apoptosis was the same
regardless of incubation temperature (Figure 4C), confirming that
all treatment conditions enabled ligand/antibody-receptor interaction.
These results argue against the compartmentalisation hypothesis.
rhTRAIL and agonistic DR4/5 antibodies phosphorylate
distinct JNK1 isoforms
To address the different effects of JNK inhibition on apoptosis, we
next investigated which JNK isoforms were phosphorylated by
rhTRAIL and the DR4/5 antibodies. JNK1 was immunoprecipitated
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Figure 3 Inhibition of JNK inhibits rhTRAIL-mediated apoptosis, but
potentiates DR4- or DR5-mediated apoptosis in colon cancer cells.
(A) L-JNKI can inhibit rhTRAIL-mediated JNK activation. HCT15 cells were
preincubated for 1 h with L-JNKI (25 mM) followed by treatment with
50 ng ml1 rhTRAIL for 3 h or UV for 30 min. The figure shows GST p-c-Jun
phosphorylation by JNK as a measure of JNK activity. (B) Inhibition of
L-JNKI potentiates apoptosis induced by selective activation of DR4 and
DR5, but reduces apoptosis induced by rhTRAIL. Colo205 cells were
treated for 3 h with either 20 ng ml1 rhTRAIL or 5 nM of DR4/DR5
agonistic antibodies with or without 30 min pretreatment with L-JNKI
(50 mM) and induction of apoptosis was measured with Annexin V. The
graph shows average cell death±s.e.m. of four independent experiments.
The asterisk (*) indicates significant differences (Po0.05). (C) Inhibition of
L-JNKI potentiates apoptosis induced by selective activation of DR4 or
DR5, but reduces apoptosis induced by rhTRAIL. HCT15 cells were
treated for 3 h with either 50 ng ml1 rhTRAIL or 10 nM of DR4/DR5
agonistic antibodies with or without 30 min pretreatment with L-JNKI
(50 mM) and induction of apoptosis was measured with Annexin V. The
graph shows average cell death±s.e.m. of three independent experiments.
The asterisk (*) indicates significant differences (Po0.05).
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from rhTRAIL-treated and agonistic antibody-treated Colo205 and
HCT15 cells. Immunoprecipitates were electrophoresed on SDS–
PAGE and probed for phosphorylated JNK, to identify which JNK1
isoforms were activated by the different treatments. For quanti-
fication, blots were also probed for total JNK1 (Figure 5A) and the
densitometric ratio of p-JNK1-long or -short to total JNK1-long or
-short was calculated (Figure 5B). In both cell lines, all treatments
could initiate phosphorylation of the short JNK1 isoform (46 kDa,
JNK1a1 and/or JNK1b1 isoforms), whereas the long isoform
(54 kDa, JNK1a2 and/or JNK1b2) was only phosphorylated after
rhTRAIL treatment (Figure 5A and B). Lysate input from all
treated samples confirmed JNK phosphorylation in both cell lines
(Figure 5A). Due to the high homology between the a1/2 and b1/2
isoforms, we could not differentiate between the a1/b1 and the
a2/b2 isoforms.
To assess which JNK2 isoforms were phosphorylated following
selective receptor activation or rhTRAIL treatment, immuno-
precipitation with JNK2-specific antibody was attempted, but was
unsuccessful due to technical difficulties (no suitable, isoform-
specific antibody was available, data not shown). As an alternative
strategy, phospho-JNK (including all JNK1 and JNK2 isoforms)
was immunoprecipitated, electrophoresed by SDS– PAGE and
probed with total JNK2 antibody (this identified whether the short
or long JNK2 isoforms were phosphorylated). Total phospho-JNK
levels of the same blots were also determined to quantify the levels
of phospho-JNK2 isoforms, in a similar manner as for the JNK1
isoforms (Figure 5C and D). The levels of phosphorylated JNK2 did
not increase from the baseline after any of the treatments,
suggesting that JNK2 is not activated by TRAIL receptors (Figure
5C and D). These data demonstrate that JNK1 is the main JNK
subtype activated by TRAIL receptors and selective activation of
DR4 or DR5 activated predominantly the short isoforms of JNK1
(JNK1a1 and/or JNK1b1) whereas rhTRAIL led to phosphorylation
of both the short and long JNK1 isoforms (ie JNK1a2 and/or
JNK1b2).
JNK1a1 has an antiapoptotic function
The above results indicated that the short isoforms of JNK1
(JNK1a1 and/or JNK1b1) may play an antiapoptotic role on
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Figure 4 Receptor internalisation induced by rhTRAIL and agonistic DR4/5 antibodies. (A) Flow cytometric analysis of ligated receptor internalisation in
Colo205 cells. Cells were treated with DR4/5 agonistic antibodies (5 nM) cross-linked with FITC-labelled secondary antibody or FITC-labelled rhTRAIL
(20 ng ml1) for 30 min at 371C or at 41C. Cells were washed with 0.2 M acetic acid to remove surface bound rhTRAIL and agonistic antibodies.
(B) Quantification of receptor internalisation. The graph shows the difference of isotype control-normalised MFI measured at 4 and 371C (normalised MFI at
371C minus normalised MFI at þ41C). The first set of bars shows the level of receptor internalisation occurred at 371C after treatment with rhTRAIL or
agonistic antibodies (normalised MFI at 371C/acid wash – normalised MFI at þ41C/acid wash). The second set of bars indicates that rhTRAIL and agonistic
DR4- and DR5 antibodies bound to the TRAIL receptors to a similar level regardless of the incubation temperature. (C) Induction of apoptosis by
treatments detailed in point a. After the 30 min incubation with rhTRAIL or antibodies, the unbound molecules were removed by a wash step and the cells
were incubated in normal growth medium for an additional 3 h after which induction cell death was measured with Annexin V. The data shown are
representative of three independent experiments.
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selective activation of DR4 or DR5. In an effort to dissect its role,
Colo205 cells were transiently transfected with an shRNA
expression plasmid to JNK1a1. RT–PCR demonstrated knock-
down of JNK1a1 following transient transfection of JNK1a1
shRNA, without affecting total JNK1 and JNK1b1 mRNA levels
confirming isotype-specific knockdown (Figure 6A; isoform
specific primer design is depicted in Supplementary Figure 2).
Accordingly, a decrease in the protein levels of the short JNK1
isoform was induced by the JNK1a1 shRNA observed by western
blotting (Figure 6B). Induction of apoptosis by TRAIL or selective
induction of DR4 or DR5 by agonistic antibodies was assessed in
JNK1a1 shRNA transfectants by Annexin V binding. Knockdown
of JNK1a1 significantly increased apoptosis induced by TRAIL, as
well as agonistic DR4- and DR5-antibodies at 3 h of exposure
(TRAIL, P¼ 0.040; DR4, P¼ 0.042; DR5, P¼ 0.046) compared to
cells transfected with a scrambled shRNA expressing plasmid
(Figure 6C). These data suggest that JNK1a1 has an antiapoptotic
effect.
The only region that differs in the long JNK1 isoforms from the
short JNK1 isoforms is a 5-nucleotide sequence and thus this was
the only region targetable by siRNA. We designed two siRNAs
against this region with selectivity for the a2/b2 isoforms (the
targeted region is highlighted in Supplementary Figure 2). The
efficiency of the knockdown was analysed by western blotting. Cell
lysates of Colo205 cells transfected with JNK1a2/b2 siRNA or
siRNA against GFP as a negative control for 24 h was analysed for
JNK1 expression, using a JNK1-specific antibody (Figure 7A).
JNK1a2/b2 siRNAs reduced the expression of the long JNK1
isoforms, without having a non-specific effect on the short JNK1
isoforms. JNK1a2/b2 siRNA transfected Colo205 cells were then
treated with rhTRAIL (40 and 60 ng ml1) for 3 h and induction of
apoptosis was measured (Figure 7B). Knockdown of the long JNK1
isoforms reduced TRAIL-induced apoptosis, indicating that these
JNK1 isoforms are indeed proapoptotic (40 ng ml1 rhTRAIL,
P¼ 0.049 and 0.04 for siRNA 1 and 2, respectively; 60 ng ml1
rhTRAIL, P¼ 0.047 and 0.04 for siRNA 1 and 2, respectively).
DISCUSSION
JNK is activated following stimulation of various TNF receptor
superfamily members, TNF-R1, Fas, DR4 and DR5 (Sluss et al,
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Figure 5 rhTRAIL and selective activation of DR4 or DR5 leads to activation of distinct JNK1 isoforms. (A) Phosphorylation of JNK1 isoforms by rhTRAIL
and agonistic DR4/5 antibodies. Colo205 cells were treated with 5 nM of agonistic DR4/5 antibodies or 20 ng ml1 rhTRAIL. HCT15 cells treated with 10 nM
of agonistic DR4/5 antibodies or 50 ng ml1 rhTRAIL for 3 h. JNK1 was immunoprecipitated (IP) and its phosphorylation pattern was assessed by western
blotting with p-JNK antibody. JNK1 western blots show total JNK1 protein immunoprecipitated from cell lysates that was used for quantification of the
amount of p-JNKI in the IP. (B) Densitometric quantification of p-JNK1 levels. The graph shows averaged p-JNK1 band densities normalised for total JNK1
levels in the immunoprecipitates of Colo205 (top) and HCT15 (bottom) cells from four independent experiments. (C) Phosphorylation of JNK2 isoforms by
rhTRAIL and agonistic DR4/5 antibodies. Colo205 and HCT15 cells were treated as in point A and p-JNK protein (both JNK1 and 2) was
immunoprecipitated. JNK2 phosphorylation was assessed in the p-JNK immunoprecipitates by probing the blots with a JNK2-specific antibody. P-JNK protein
levels were also determined for quantification of JNK2 phosphorylation. (D) Densitometric quantification of p-JNK2 levels in Colo205 (left) and HCT15
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1994; Cahill et al, 1996; Yang et al, 1997; Herr et al, 1999). The role
of this JNK activation in apoptosis is unclear and opposing, pro-
and antiapoptotic functions have been proposed (Bode and Dong,
2007; Yoo et al, 2008). Similarly, controversy exists as to the role
that activated JNK might play in TRAIL-induced colon carcinoma
apoptosis (Zhang et al, 2004). This study demonstrates that in
colon carcinoma cells that express both DR4 and DR5, both
receptors are able to trigger JNK activation and c-Jun phosphory-
lation. To elucidate the role of JNK activation in DR4- and DR5-
mediated apoptosis in colon carcinoma cells, JNK activity was
blocked by L-JNKI. L-JNKI was chosen over the widely used
SP600125 (Bennett et al, 2001) as recent studies found that
SP600125 is a rather non-specific JNK inhibitor (Bain et al, 2003).
Our studies found that inhibition of JNK by L-JNKI reduced
rhTRAIL-induced cell death, suggesting a proapoptotic role for
JNK. Interestingly, inhibition of JNK potentiated cell death
induced by selective activation of DR4 or DR5, suggesting that
depending on the type or the total number of receptors activated, a
pro- or antiapoptotic JNK signal transduction pathway can be
activated.
It has been shown that after binding to its receptors, TRAIL is
rapidly internalised by both clathrin-dependent and -independent
endocytosis (Kohlhaas et al, 2007). Unlike TNF-R1, internalisation
is not required for TRAIL-induced apoptosis, as the assembly of
the TRAIL DISC already occurs at the cell membrane (Kohlhaas
et al, 2007). However, internalisation of the ligated receptor has
been suggested to play a role in other TRAIL-mediated signalling
events such as activation of JNK or NF-kB (Varfolomeev et al,
2005). In our hands, internalisation of TRAIL receptors ligated by
agonistic DR4 and DR5 antibodies or by rhTRAIL revealed no
significant differences; in all cases, the ligated receptor complex
was rapidly internalised. This indicates that the opposing
apoptosis-modulatory effect of JNK activation induced by TRAIL
or selective DR4/DR5 activation was not due to receptor
internalisation but possibly different isoforms of JNK activated
by the individual receptors.
Ten isoforms of JNK are known to exist as a result of alternative
splicing of the three genes, jnk1, jnk2 and jnk3 (Gupta et al, 1996).
Little is known about the role of these isoforms in apoptosis.
Overexpression of JNK1b1 increases resistance to vesicular
stomatitis virus-induced cell death in 3T3 fibroblasts, whereas
overexpression of JNK1a1 and JNK1b1 potentiates cisplatin- and
doxorubicin-induced cell death in sarcoma cell lines (Han et al,
2002; Koyama et al, 2006). Previous studies have demonstrated a
role for either JNK1 or JNK2 in TNFa-induced apoptosis (Dietrich
et al, 2004; Liu et al, 2004). Our results show that the chief JNK
isotype activated by DR4 and DR5 is JNK1. Furthermore, whereas
TRAIL-mediated receptor activation led to activation of both the
long and short isoforms of JNK1, selective ligation of DR4 or DR5
with cross-linked agonistic antibodies predominantly activated the
short JNK1 isoforms (JNK1a1 and/or b1) and the difference in cell
death seen following JNK inhibition may be related to the different
JNK1 isoforms, with the short isoforms of JNK1 (JNK1a1 and
JNK1b1) transmitting an antiapoptotic signal and the long
isoforms of JNK1 (JNK1a2 or JNK1b2) mediating a proapoptotic
signal. As a reason why activation of individual TRAIL receptors
by agonistic antibodies activates different JNK isoforms from
rhTRAIL, it is likely that the agonistic DR4- and DR5-specific
antibodies trigger different receptor clustering, or intracellular
conformational changes from those induced by rhTRAIL. It is also
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possible that on rhTRAIL treatment, higher-order heteromeric
receptor complexes (receptosomes) including both DR4 and DR5
are formed where the interaction between the death domains of the
various receptor trimers allows for the recruitment of more and/or
different adaptor proteins. It has been shown that different
agonists of DR4 and DR5 (agonistic antibodies and recombinant
ligand) trigger different conformational changes in the receptors
resulting in differences in adaptor protein recruitment, such as
FADD. This can lead to activation of different downstream signal
transduction and kinase pathways (Thomas et al, 2004).
Our current studies investigate this possibility. Of note, in both
Colo205 and HCT15 cells, rhTRAIL was a more efficient inducer of
apoptosis than either DR4 or DR5 agonistic antibodies. This may
be in line with the hypothesis that full signal transduction requires
both DR4 and DR5 activation simultaneously.
To elucidate the roles of the different JNK1 isoforms, JNK1a1
expression as well as JNK1a2/b2 expression was knocked down
with shRNA. Knockdown of the short JNK1 isoform potentiated
TRAIL-induced apoptosis, whereas elimination of the long JNK1
isoforms blocked rhTRAIL-induced cell death. These results
demonstrate that the short JNK1 isoform, JNK1a1 acts against
apoptosis, whereas the long JNK1 isoforms promote it. In has to be
noted, that knocking down JNK efficiently (as JNK is an abundant
protein) is very difficult. Even 30– 50% of the remaining protein
may be sufficient to transmit a signal. Selective targeting one JNK
isoform is even more complicated and thus our method probably
underestimated the real potency of JNK isoforms in modulating
TRAIL-mediated apoptosis.
Genes regulated by JNK1a1 and JNK1b1 have been previously
identified by Han et al (2002). Overexpression of a constitutively
active form of JNK1a1 led to the induction of a number of
antiapoptotic/prosurvival genes including proliferin (mitogen-
regulated protein), Ack protein tyrosine kinase and serum and
glucocorticoid regulated kinase (sgk) and repression of proapop-
totic proteins, such as insulin-like growth factor binding protein-4
(IGFBP-4) and suppressor of cytokine signalling-3 (SOCS-3) as a
strong indication that JNK1a1 indeed triggers antiapoptotic
signalling (Han et al, 2002). Identifying which of these genes, or
other so far unidentified genes, play important role warrants
further studies.
In conclusion, we show for the first time that combined
activation of all TRAIL receptors vs selective activation of DR4
or DR5 result in the activation of different JNK isoforms.
Moreover, the short isoform of JNK1, JNK1a1, generates an
antiapoptotic signal whereas the long isoforms of JNK1 trigger
proapoptotic signalling. Our findings shed light on the apparently
contradictory results surrounding the role of JNK signalling in
TRAIL-induced apoptosis and also suggest a way forward to target
cancer cells for sensitisation to killing by inhibition of short
isoforms of JNK1.
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